RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.
Modalis wins FDA rare paediatric designation for CMD CRISPR therapy – Pharmaceutical Technology
LAMA2-CMD is an early onset congenital muscular dystrophy caused by the absence of the LAMA2 protein. Image credit: Shutterstock/ Dan76. Modalis Therapeutics has been awarded